Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

Screen patients for AATD: position statement from TSANZ

Recommendation to lift PBS restrictions on ICS+LABA access in children

This surgeon wants smokers to be banned from having surgery – until they quit

Experts question blood eosinophil cut-offs in GINA, GOLD

Urgent need for a national health protection strategy against bushfire smoke

Lung cancer

Disappointing results for mesothelioma trial

By Nicola Garrett

15 Oct 2019

Data from the highly anticipated PROMISE-meso trial failed to deliver, with no PFS or OS benefit seen for pembrolizumab compared to standard chemotherapy. The Phase III trial, presented at the European Society for Medical Oncology Congress 2019 in Barcelona, involved 144 patients with advanced pre-treated mesothelioma who were randomised to pembrolizumab (200 mg every three ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel

Top Stories